ArticleMolecular neurobiology2026
TFE3 Regulates Microglial Phagocytosis and Inflammation in MPTP-induced Parkinson's Disease.
Article in Molecular neurobiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson's disease (PD) is a common neurodegenerative disease. Our previous single-cell sequencing results suggested that Transcription Factor E3 (TFE3) was only differentially expressed in microglia in the MPTP mouse model. However, the functional role of microglial TFE3 in PD pathogenesis remains unclear. First, motor function was assessed in MPTP mice following TFE3 overexpression in substantia nigra microglia. Second, RNA-seq was used to identify the function of TFE3 in microglia, and the molecular mechanism was verified both in vivo and in vitro. Finally, we investigated whether TFE3 nuclear translocation affects its transcriptional activity and subsequently influences microglia in vitro. Overexpression of TFE3 in substantia nigra microglia could alleviate PD-related phenotypes. RNA-seq revealed that TFE3 regulates microglial phagocytosis and inflammation. Mechanistically, TFE3 affects these functions by regulating the expression of Mer receptor tyrosine kinase (Mertk) and lysosomal-associated membrane protein 1 (Lamp1). Finally, Rapamycin could activate the nuclear translocation of TFE3 and enhance phagocytosis and alleviate inflammation of microglia. Our findings demonstrate that Rapamycin activates TFE3, which in turn upregulates the expression of Mertk and Lamp1 in the substantia nigra. This TFE3-mediated pathway plays a critical role in regulating microglial phagocytosis and inflammation in the PD model.
Indexed as
Identifiers
42334745What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.